Frequency and Significance of L265P MyD88 Mutations in Primary Central Nervous System Lymphomas

被引：0
|
作者：
Grzywacz, B.
Lin, J. J.
Nolling, J.
Bodo, J.
Collie, A. M. B.
Durkin, L.
Manilich, E.
Kong, L.
Jegalian, A. G.
Hsi, E. D.
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] PrimeraDx, Mansfield, MA USA
来源：
LABORATORY INVESTIGATION | 2014年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1440
引用
收藏
页码：349A / 350A
页数：2
相关论文
共 50 条
  • [1] Frequency and Significance of L265P MyD88 Mutations in Primary Central Nervous System Lymphomas
    Grzywacz, B.
    Lin, J. J.
    Nolling, J.
    Bodo, J.
    Collie, A. M. B.
    Durkin, L.
    Manilich, E.
    Kong, L.
    Jegalian, A. G.
    Hsi, E. D.
    MODERN PATHOLOGY, 2014, 27 : 349A - 350A
  • [2] Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma
    Montesinos-Rongen, Manuel
    Godlewska, Elzbieta
    Brunn, Anna
    Wiestler, Otmar D.
    Siebert, Reiner
    Deckert, Martina
    ACTA NEUROPATHOLOGICA, 2011, 122 (06) : 791 - 792
  • [3] Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma
    Manuel Montesinos-Rongen
    Elzbieta Godlewska
    Anna Brunn
    Otmar D. Wiestler
    Reiner Siebert
    Martina Deckert
    Acta Neuropathologica, 2011, 122 : 791 - 792
  • [4] MYD88 (L265P) MUTATION IS ASSOCIATED WITH AN UNFAVORABLE OUTCOME OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
    Hattori, K.
    Sakata-Yanagimoto, M.
    Okoshi, Y.
    Goshima, Y.
    Yanagimoto, S.
    Nakamoto-Matsubara, R.
    Sato, T.
    Noguchi, M.
    Takano, S.
    Ishikawa, E.
    Yamamoto, T.
    Matsumura, A.
    Chiba, S.
    HAEMATOLOGICA, 2016, 101 : 392 - 393
  • [5] MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma
    Hattori, Keiichiro
    Sakata-Yanagimoto, Mamiko
    Okoshi, Yasushi
    Goshima, Yuki
    Yanagimoto, Shintaro
    Nakamoto-Matsubara, Rie
    Sato, Taiki
    Noguchi, Masayuki
    Takano, Shingo
    Ishikawa, Eichi
    Yamamoto, Tetsuya
    Matsumura, Akira
    Chiba, Shigeru
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (03) : 492 - 494
  • [6] MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas
    White, Michael
    Brastianos, Priscilla Kaliopi
    Batchelor, Tracy
    Nayyar, Naema
    Gill, Corey
    Lastrapes, Matt
    Bertalan, Mia
    Kaplan, Alex
    D'Andrea, Meghan
    Bihun, Ivanna
    Kaneb, Andrew
    Dietrich, Jorg
    Ferry, Judith
    Alvarez, Maria Martinez-Lage
    Giobbie-Hurder, Anita
    Borger, Darrell R.
    Rodriguez, Fausto J.
    Holdhoff, Matthias
    Cahill, Daniel P.
    Carter, Scott L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation
    Li, Wei
    Wang, Ruirui
    Wang, Junhao
    Chai, Dafei
    Xie, Xiaohui
    Young, Ken H.
    Cao, Ya
    Li, Yong
    Yu, Xinfang
    BLOOD, 2025, 145 (10) : 1047 - 1060
  • [8] Therapy for MYD88 L265P DLBCL
    Vermaat, Joost S. P.
    de Groen, Ruben A. L.
    BLOOD, 2025, 145 (10) : 998 - 1000
  • [9] MYD88 L265P Mutation Studies in HIV-Associated Lymphomas
    Ahooja, M. S.
    Shetty, O. A.
    Gurav, M. Y.
    Uttarkar, A.
    Gupta, M.
    Sengar, M.
    Epari, S.
    Shet, T.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 770 - 770
  • [10] Significance of MYD88 L265P Mutation Status and EBV Latency Programs in Primary Central Nervous System Lymphoproliferative Disorders in Immunocompromised and Immunocompetent Individuals
    Cantu, Miguel
    Yamshon, Samuel
    Rutherford, Sarah
    Mwangi, Raphael
    Habermann, Thomas
    King, Rebecca
    Kluk, Michael
    Chadburn, Amy
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 810 - 811
12345